PandemieGrippaleV1, PascalFrancis, Curation, bibRecord, 001C11

Evaluation of Three Influenza Neuraminidase Inhibition Assays for Use in a Public Health Laboratory Setting During the 2011-2012 Influenza Season

Identifieur interne : 001C11 ( PascalFrancis/Curation ); précédent : 001C10; suivant : 001C12

Evaluation of Three Influenza Neuraminidase Inhibition Assays for Use in a Public Health Laboratory Setting During the 2011-2012 Influenza Season

Auteurs : William Murtaugh [États-Unis] ; Lalla Mahaman [États-Unis] ; Benjamin Healey [États-Unis] ; Heather Peters [États-Unis] ; Barbara Anderson [États-Unis] ; Mandy Tran [États-Unis] ; Marci Ziese [États-Unis] ; Maria Paz Carlos [États-Unis]

Source :

Public health reports : (1974) [ 0033-3549 ] ; 2013.

RBID : Pascal:13-0326981

Descripteurs français

Pascal (Inist)
- Grippe, Evaluation, Exo-α-sialidase, Dosage, Utilisation, Santé publique, Laboratoire, Service santé, Saison.
Wicri :
- topic : Santé publique.

English descriptors

KwdEn :
- Assay, Evaluation, Exo-α-sialidase, Health service, Influenza, Laboratory, Public health, Season, Use.

Abstract

Objectives. We evaluated the implementation of three commericially available neuraminidase inhibition assays in a public health laboratory (PHL) setting. We also described the drug susceptibility patterns of human influenza A and B circulating in Maryland during the 2011-2012 influenza season. Methods. From January to May 2012, 169 influenza virus isolates were tested for phenotypic susceptibility to oseltamivir, zanamivir, and peramivir using NA-Fluor<^TM>, NA-Star®, and NA-XTD<^TM> concurrently. A 50% neuraminidase inhibitory concentration (IC₅₀) value was calculated to determine drug susceptibility. We used the standard deviation based on the median absolute deviation of the median analysis to determine the potential for reduced drug susceptibility. We evaluated each assay for the use of resources in high- and low-volume testing scenarios. Results. One of the 25 2009 influenza A (H1N1) pandemic isolates tested was resistant to oseltamivir and peramivir, and sensitive to zanamivir, on all three platforms. Eighty-two influenza A (H3N2) and 62 B isolates were sensitive to all three drugs in all three assays. For a low-volume scenario, NA-Star and NA-XTD took 120 minutes to complete, while NA-Fluor required 300 minutes to complete. The lowest relative cost favored NA-Star. In a high-volume scenario, NA-Fluor had the highest throughput. Reagent use was most efficient when maximizing throughput. Cost efficiency from low- to high-volume testing improved the most for NA-Star. Conclusions. Our evaluation showed that both chemiluminescent and fluorescent neuraminidase inhibition assays can be successfully implemented in a PHL setting to screen circulating influenza strains for neuraminidase inhibitor resistance. For improved PHL influenza surveillance, it may be essential to develop guidelines for phenotypic drug-resistance testing that take into consideration a PHL's workload and available resources.

A01	`01`	`1`		`@0 0033-3549`
A02	`01`			`@0 PHRPA6`
A03		`1`		`@0 Public health rep. : (1974)`
A05				`@2 128`
A06				`@3 SUP2`
A08	`01`	`1`	`ENG`	`@1 Evaluation of Three Influenza Neuraminidase Inhibition Assays for Use in a Public Health Laboratory Setting During the 2011-2012 Influenza Season`
A09	`01`	`1`	`ENG`	`@1 Public Health Laboratory Systems: At the Crossroads`
A11	`01`	`1`		`@1 MURTAUGH (William)`
A11	`02`	`1`		`@1 MAHAMAN (Lalla)`
A11	`03`	`1`		`@1 HEALEY (Benjamin)`
A11	`04`	`1`		`@1 PETERS (Heather)`
A11	`05`	`1`		`@1 ANDERSON (Barbara)`
A11	`06`	`1`		`@1 TRAN (Mandy)`
A11	`07`	`1`		`@1 ZIESE (Marci)`
A11	`08`	`1`		`@1 CARLOS (Maria Paz)`
A12	`01`	`1`		`@1 RIDDERHOF (John C.) @9 ed.`
A12	`02`	`1`		`@1 WILCKE (Burton W.) @9 ed.`
A14	`01`			`@1 State of Maryland Department of Health and Mental Hygiene, Laboratories Administration, Division of Virology and Immunology @2 Baltimore, MD @3 USA @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut. @Z 7 aut. @Z 8 aut.`
A14	`02`			`@1 Johns Hopkins Bloomberg School of Public Health @2 Baltimore, MD @3 USA @Z 1 aut. @Z 8 aut.`
A15	`01`			`@1 Centers for Disease Control and Prevention, Office of Surveillance, Epidemiology and Laboratory Services, Laboratory Science, Policy and Practice Program Office, 1600 Clifton Rd. NE, MS-E94 @2 Atlanta, GA 30333 @3 USA @Z 1 aut.`
A15	`02`			`@1 Department of Medical Laboratory and Radiation Sciences, College of Nursing and Health Sciences, the University of Vermont at Burlington @2 Burlington, Vermont @3 USA @Z 2 aut.`
A20				`@1 75-87`
A21				`@1 2013`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 3073 @5 354000501574530110`
A44				`@0 0000 @1 © 2013 INIST-CNRS. All rights reserved.`
A45				`@0 21 ref.`
A47	`01`	`1`		`@0 13-0326981`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Public health reports : (1974)`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Objectives. We evaluated the implementation of three commericially available neuraminidase inhibition assays in a public health laboratory (PHL) setting. We also described the drug susceptibility patterns of human influenza A and B circulating in Maryland during the 2011-2012 influenza season. Methods. From January to May 2012, 169 influenza virus isolates were tested for phenotypic susceptibility to oseltamivir, zanamivir, and peramivir using NA-Fluor<^TM>, NA-Star®, and NA-XTD<^TM> concurrently. A 50% neuraminidase inhibitory concentration (IC₅₀) value was calculated to determine drug susceptibility. We used the standard deviation based on the median absolute deviation of the median analysis to determine the potential for reduced drug susceptibility. We evaluated each assay for the use of resources in high- and low-volume testing scenarios. Results. One of the 25 2009 influenza A (H1N1) pandemic isolates tested was resistant to oseltamivir and peramivir, and sensitive to zanamivir, on all three platforms. Eighty-two influenza A (H3N2) and 62 B isolates were sensitive to all three drugs in all three assays. For a low-volume scenario, NA-Star and NA-XTD took 120 minutes to complete, while NA-Fluor required 300 minutes to complete. The lowest relative cost favored NA-Star. In a high-volume scenario, NA-Fluor had the highest throughput. Reagent use was most efficient when maximizing throughput. Cost efficiency from low- to high-volume testing improved the most for NA-Star. Conclusions. Our evaluation showed that both chemiluminescent and fluorescent neuraminidase inhibition assays can be successfully implemented in a PHL setting to screen circulating influenza strains for neuraminidase inhibitor resistance. For improved PHL influenza surveillance, it may be essential to develop guidelines for phenotypic drug-resistance testing that take into consideration a PHL's workload and available resources.
C02	`01`	`X`		`@0 002B05C02C`
C02	`02`	`X`		`@0 002B30A11`
C03	`01`	`X`	`FRE`	`@0 Grippe @5 01`
C03	`01`	`X`	`ENG`	`@0 Influenza @5 01`
C03	`01`	`X`	`SPA`	`@0 Gripe @5 01`
C03	`02`	`X`	`FRE`	`@0 Evaluation @5 07`
C03	`02`	`X`	`ENG`	`@0 Evaluation @5 07`
C03	`02`	`X`	`SPA`	`@0 Evaluación @5 07`
C03	`03`	`X`	`FRE`	`@0 Exo-α-sialidase @2 FE @5 08`
C03	`03`	`X`	`ENG`	`@0 Exo-α-sialidase @2 FE @5 08`
C03	`03`	`X`	`SPA`	`@0 Exo-α-sialidase @2 FE @5 08`
C03	`04`	`X`	`FRE`	`@0 Dosage @5 09`
C03	`04`	`X`	`ENG`	`@0 Assay @5 09`
C03	`04`	`X`	`SPA`	`@0 Dosificación @5 09`
C03	`05`	`X`	`FRE`	`@0 Utilisation @5 13`
C03	`05`	`X`	`ENG`	`@0 Use @5 13`
C03	`05`	`X`	`SPA`	`@0 Uso @5 13`
C03	`06`	`X`	`FRE`	`@0 Santé publique @5 14`
C03	`06`	`X`	`ENG`	`@0 Public health @5 14`
C03	`06`	`X`	`SPA`	`@0 Salud pública @5 14`
C03	`07`	`X`	`FRE`	`@0 Laboratoire @5 15`
C03	`07`	`X`	`ENG`	`@0 Laboratory @5 15`
C03	`07`	`X`	`SPA`	`@0 Laboratorio @5 15`
C03	`08`	`X`	`FRE`	`@0 Service santé @5 16`
C03	`08`	`X`	`ENG`	`@0 Health service @5 16`
C03	`08`	`X`	`SPA`	`@0 Servicio sanidad @5 16`
C03	`09`	`X`	`FRE`	`@0 Saison @5 17`
C03	`09`	`X`	`ENG`	`@0 Season @5 17`
C03	`09`	`X`	`SPA`	`@0 Estación @5 17`
C07	`01`	`X`	`FRE`	`@0 Virose`
C07	`01`	`X`	`ENG`	`@0 Viral disease`
C07	`01`	`X`	`SPA`	`@0 Virosis`
C07	`02`	`X`	`FRE`	`@0 Infection`
C07	`02`	`X`	`ENG`	`@0 Infection`
C07	`02`	`X`	`SPA`	`@0 Infección`
C07	`03`	`X`	`FRE`	`@0 Glycosidases @2 FE`
C07	`03`	`X`	`ENG`	`@0 Glycosidases @2 FE`
C07	`03`	`X`	`SPA`	`@0 Glycosidases @2 FE`
C07	`04`	`X`	`FRE`	`@0 Glycosylases @2 FE`
C07	`04`	`X`	`ENG`	`@0 Glycosylases @2 FE`
C07	`04`	`X`	`SPA`	`@0 Glycosylases @2 FE`
C07	`05`	`X`	`FRE`	`@0 Hydrolases @2 FE`
C07	`05`	`X`	`ENG`	`@0 Hydrolases @2 FE`
C07	`05`	`X`	`SPA`	`@0 Hydrolases @2 FE`
C07	`06`	`X`	`FRE`	`@0 Enzyme @2 FE`
C07	`06`	`X`	`ENG`	`@0 Enzyme @2 FE`
C07	`06`	`X`	`SPA`	`@0 Enzima @2 FE`
N21				`@1 308`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000216

Links to Exploration step

Pascal:13-0326981

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Evaluation of Three Influenza Neuraminidase Inhibition Assays for Use in a Public Health Laboratory Setting During the 2011-2012 Influenza Season</title>
<author><name sortKey="Murtaugh, William" sort="Murtaugh, William" uniqKey="Murtaugh W" first="William" last="Murtaugh">William Murtaugh</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>State of Maryland Department of Health and Mental Hygiene, Laboratories Administration, Division of Virology and Immunology</s1>
<s2>Baltimore, MD</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Johns Hopkins Bloomberg School of Public Health</s1>
<s2>Baltimore, MD</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Mahaman, Lalla" sort="Mahaman, Lalla" uniqKey="Mahaman L" first="Lalla" last="Mahaman">Lalla Mahaman</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>State of Maryland Department of Health and Mental Hygiene, Laboratories Administration, Division of Virology and Immunology</s1>
<s2>Baltimore, MD</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Healey, Benjamin" sort="Healey, Benjamin" uniqKey="Healey B" first="Benjamin" last="Healey">Benjamin Healey</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>State of Maryland Department of Health and Mental Hygiene, Laboratories Administration, Division of Virology and Immunology</s1>
<s2>Baltimore, MD</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Peters, Heather" sort="Peters, Heather" uniqKey="Peters H" first="Heather" last="Peters">Heather Peters</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>State of Maryland Department of Health and Mental Hygiene, Laboratories Administration, Division of Virology and Immunology</s1>
<s2>Baltimore, MD</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Anderson, Barbara" sort="Anderson, Barbara" uniqKey="Anderson B" first="Barbara" last="Anderson">Barbara Anderson</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>State of Maryland Department of Health and Mental Hygiene, Laboratories Administration, Division of Virology and Immunology</s1>
<s2>Baltimore, MD</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Tran, Mandy" sort="Tran, Mandy" uniqKey="Tran M" first="Mandy" last="Tran">Mandy Tran</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>State of Maryland Department of Health and Mental Hygiene, Laboratories Administration, Division of Virology and Immunology</s1>
<s2>Baltimore, MD</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Ziese, Marci" sort="Ziese, Marci" uniqKey="Ziese M" first="Marci" last="Ziese">Marci Ziese</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>State of Maryland Department of Health and Mental Hygiene, Laboratories Administration, Division of Virology and Immunology</s1>
<s2>Baltimore, MD</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Carlos, Maria Paz" sort="Carlos, Maria Paz" uniqKey="Carlos M" first="Maria Paz" last="Carlos">Maria Paz Carlos</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>State of Maryland Department of Health and Mental Hygiene, Laboratories Administration, Division of Virology and Immunology</s1>
<s2>Baltimore, MD</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Johns Hopkins Bloomberg School of Public Health</s1>
<s2>Baltimore, MD</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">13-0326981</idno>
<date when="2013">2013</date>
<idno type="stanalyst">PASCAL 13-0326981 INIST</idno>
<idno type="RBID">Pascal:13-0326981</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000216</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001C11</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Evaluation of Three Influenza Neuraminidase Inhibition Assays for Use in a Public Health Laboratory Setting During the 2011-2012 Influenza Season</title>
<author><name sortKey="Murtaugh, William" sort="Murtaugh, William" uniqKey="Murtaugh W" first="William" last="Murtaugh">William Murtaugh</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>State of Maryland Department of Health and Mental Hygiene, Laboratories Administration, Division of Virology and Immunology</s1>
<s2>Baltimore, MD</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Johns Hopkins Bloomberg School of Public Health</s1>
<s2>Baltimore, MD</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Mahaman, Lalla" sort="Mahaman, Lalla" uniqKey="Mahaman L" first="Lalla" last="Mahaman">Lalla Mahaman</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>State of Maryland Department of Health and Mental Hygiene, Laboratories Administration, Division of Virology and Immunology</s1>
<s2>Baltimore, MD</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Healey, Benjamin" sort="Healey, Benjamin" uniqKey="Healey B" first="Benjamin" last="Healey">Benjamin Healey</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>State of Maryland Department of Health and Mental Hygiene, Laboratories Administration, Division of Virology and Immunology</s1>
<s2>Baltimore, MD</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Peters, Heather" sort="Peters, Heather" uniqKey="Peters H" first="Heather" last="Peters">Heather Peters</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>State of Maryland Department of Health and Mental Hygiene, Laboratories Administration, Division of Virology and Immunology</s1>
<s2>Baltimore, MD</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Anderson, Barbara" sort="Anderson, Barbara" uniqKey="Anderson B" first="Barbara" last="Anderson">Barbara Anderson</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>State of Maryland Department of Health and Mental Hygiene, Laboratories Administration, Division of Virology and Immunology</s1>
<s2>Baltimore, MD</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Tran, Mandy" sort="Tran, Mandy" uniqKey="Tran M" first="Mandy" last="Tran">Mandy Tran</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>State of Maryland Department of Health and Mental Hygiene, Laboratories Administration, Division of Virology and Immunology</s1>
<s2>Baltimore, MD</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Ziese, Marci" sort="Ziese, Marci" uniqKey="Ziese M" first="Marci" last="Ziese">Marci Ziese</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>State of Maryland Department of Health and Mental Hygiene, Laboratories Administration, Division of Virology and Immunology</s1>
<s2>Baltimore, MD</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Carlos, Maria Paz" sort="Carlos, Maria Paz" uniqKey="Carlos M" first="Maria Paz" last="Carlos">Maria Paz Carlos</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>State of Maryland Department of Health and Mental Hygiene, Laboratories Administration, Division of Virology and Immunology</s1>
<s2>Baltimore, MD</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Johns Hopkins Bloomberg School of Public Health</s1>
<s2>Baltimore, MD</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Public health reports : (1974)</title>
<title level="j" type="abbreviated">Public health rep. : (1974)</title>
<idno type="ISSN">0033-3549</idno>
<imprint><date when="2013">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Public health reports : (1974)</title>
<title level="j" type="abbreviated">Public health rep. : (1974)</title>
<idno type="ISSN">0033-3549</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Assay</term>
<term>Evaluation</term>
<term>Exo-α-sialidase</term>
<term>Health service</term>
<term>Influenza</term>
<term>Laboratory</term>
<term>Public health</term>
<term>Season</term>
<term>Use</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Grippe</term>
<term>Evaluation</term>
<term>Exo-α-sialidase</term>
<term>Dosage</term>
<term>Utilisation</term>
<term>Santé publique</term>
<term>Laboratoire</term>
<term>Service santé</term>
<term>Saison</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Santé publique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Objectives. We evaluated the implementation of three commericially available neuraminidase inhibition assays in a public health laboratory (PHL) setting. We also described the drug susceptibility patterns of human influenza A and B circulating in Maryland during the 2011-2012 influenza season. Methods. From January to May 2012, 169 influenza virus isolates were tested for phenotypic susceptibility to oseltamivir, zanamivir, and peramivir using NA-Fluor<<sup>TM</sup>
>, NA-Star®, and NA-XTD<<sup>TM</sup>
> concurrently. A 50% neuraminidase inhibitory concentration (IC<sub>50</sub>
) value was calculated to determine drug susceptibility. We used the standard deviation based on the median absolute deviation of the median analysis to determine the potential for reduced drug susceptibility. We evaluated each assay for the use of resources in high- and low-volume testing scenarios. Results. One of the 25 2009 influenza A (H1N1) pandemic isolates tested was resistant to oseltamivir and peramivir, and sensitive to zanamivir, on all three platforms. Eighty-two influenza A (H3N2) and 62 B isolates were sensitive to all three drugs in all three assays. For a low-volume scenario, NA-Star and NA-XTD took 120 minutes to complete, while NA-Fluor required 300 minutes to complete. The lowest relative cost favored NA-Star. In a high-volume scenario, NA-Fluor had the highest throughput. Reagent use was most efficient when maximizing throughput. Cost efficiency from low- to high-volume testing improved the most for NA-Star. Conclusions. Our evaluation showed that both chemiluminescent and fluorescent neuraminidase inhibition assays can be successfully implemented in a PHL setting to screen circulating influenza strains for neuraminidase inhibitor resistance. For improved PHL influenza surveillance, it may be essential to develop guidelines for phenotypic drug-resistance testing that take into consideration a PHL's workload and available resources.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0033-3549</s0>
</fA01>
<fA02 i1="01"><s0>PHRPA6</s0>
</fA02>
<fA03 i2="1"><s0>Public health rep. : (1974)</s0>
</fA03>
<fA05><s2>128</s2>
</fA05>
<fA06><s3>SUP2</s3>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Evaluation of Three Influenza Neuraminidase Inhibition Assays for Use in a Public Health Laboratory Setting During the 2011-2012 Influenza Season</s1>
</fA08>
<fA09 i1="01" i2="1" l="ENG"><s1>Public Health Laboratory Systems: At the Crossroads</s1>
</fA09>
<fA11 i1="01" i2="1"><s1>MURTAUGH (William)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>MAHAMAN (Lalla)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>HEALEY (Benjamin)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>PETERS (Heather)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>ANDERSON (Barbara)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>TRAN (Mandy)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>ZIESE (Marci)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>CARLOS (Maria Paz)</s1>
</fA11>
<fA12 i1="01" i2="1"><s1>RIDDERHOF (John C.)</s1>
<s9>ed.</s9>
</fA12>
<fA12 i1="02" i2="1"><s1>WILCKE (Burton W.)</s1>
<s9>ed.</s9>
</fA12>
<fA14 i1="01"><s1>State of Maryland Department of Health and Mental Hygiene, Laboratories Administration, Division of Virology and Immunology</s1>
<s2>Baltimore, MD</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Johns Hopkins Bloomberg School of Public Health</s1>
<s2>Baltimore, MD</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA15 i1="01"><s1>Centers for Disease Control and Prevention, Office of Surveillance, Epidemiology and Laboratory Services, Laboratory Science, Policy and Practice Program Office, 1600 Clifton Rd. NE, MS-E94</s1>
<s2>Atlanta, GA 30333</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA15>
<fA15 i1="02"><s1>Department of Medical Laboratory and Radiation Sciences, College of Nursing and Health Sciences, the University of Vermont at Burlington</s1>
<s2>Burlington, Vermont</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</fA15>
<fA20><s1>75-87</s1>
</fA20>
<fA21><s1>2013</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>3073</s2>
<s5>354000501574530110</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2013 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>21 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>13-0326981</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Public health reports : (1974)</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Objectives. We evaluated the implementation of three commericially available neuraminidase inhibition assays in a public health laboratory (PHL) setting. We also described the drug susceptibility patterns of human influenza A and B circulating in Maryland during the 2011-2012 influenza season. Methods. From January to May 2012, 169 influenza virus isolates were tested for phenotypic susceptibility to oseltamivir, zanamivir, and peramivir using NA-Fluor<<sup>TM</sup>
>, NA-Star®, and NA-XTD<<sup>TM</sup>
> concurrently. A 50% neuraminidase inhibitory concentration (IC<sub>50</sub>
) value was calculated to determine drug susceptibility. We used the standard deviation based on the median absolute deviation of the median analysis to determine the potential for reduced drug susceptibility. We evaluated each assay for the use of resources in high- and low-volume testing scenarios. Results. One of the 25 2009 influenza A (H1N1) pandemic isolates tested was resistant to oseltamivir and peramivir, and sensitive to zanamivir, on all three platforms. Eighty-two influenza A (H3N2) and 62 B isolates were sensitive to all three drugs in all three assays. For a low-volume scenario, NA-Star and NA-XTD took 120 minutes to complete, while NA-Fluor required 300 minutes to complete. The lowest relative cost favored NA-Star. In a high-volume scenario, NA-Fluor had the highest throughput. Reagent use was most efficient when maximizing throughput. Cost efficiency from low- to high-volume testing improved the most for NA-Star. Conclusions. Our evaluation showed that both chemiluminescent and fluorescent neuraminidase inhibition assays can be successfully implemented in a PHL setting to screen circulating influenza strains for neuraminidase inhibitor resistance. For improved PHL influenza surveillance, it may be essential to develop guidelines for phenotypic drug-resistance testing that take into consideration a PHL's workload and available resources.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B05C02C</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B30A11</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Grippe</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Influenza</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Gripe</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Evaluation</s0>
<s5>07</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Evaluation</s0>
<s5>07</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Evaluación</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Exo-α-sialidase</s0>
<s2>FE</s2>
<s5>08</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Exo-α-sialidase</s0>
<s2>FE</s2>
<s5>08</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Exo-α-sialidase</s0>
<s2>FE</s2>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Dosage</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Assay</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Dosificación</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Utilisation</s0>
<s5>13</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Use</s0>
<s5>13</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Uso</s0>
<s5>13</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Santé publique</s0>
<s5>14</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Public health</s0>
<s5>14</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Salud pública</s0>
<s5>14</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Laboratoire</s0>
<s5>15</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Laboratory</s0>
<s5>15</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Laboratorio</s0>
<s5>15</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Service santé</s0>
<s5>16</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Health service</s0>
<s5>16</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Servicio sanidad</s0>
<s5>16</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Saison</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Season</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Estación</s0>
<s5>17</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Glycosidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Glycosidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Glycosidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Glycosylases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Glycosylases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Glycosylases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Enzima</s0>
<s2>FE</s2>
</fC07>
<fN21><s1>308</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C11 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 001C11 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    PandemieGrippaleV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:13-0326981
   |texte=   Evaluation of Three Influenza Neuraminidase Inhibition Assays for Use in a Public Health Laboratory Setting During the 2011-2012 Influenza Season
}}

This area was generated with Dilib version V0.6.34.
Data generation: Wed Jun 10 11:04:28 2020. Site generation: Sun Mar 28 09:10:28 2021

	Serveur d'exploration sur les pandémies grippales
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les pandémies grippales

Evaluation of Three Influenza Neuraminidase Inhibition Assays for Use in a Public Health Laboratory Setting During the 2011-2012 Influenza Season

Evaluation of Three Influenza Neuraminidase Inhibition Assays for Use in a Public Health Laboratory Setting During the 2011-2012 Influenza Season

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri